(S1 (S (NP (NP (NN IL-10) (NN Production)) (PP (IN by) (NP (NN Th1) (NNS Cells)))) (VP (VBZ Requires) (NP (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2))) (NN Activation)))))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (NN IL-10) (NN induction)) (PP (IN in) (NP (NN Th1) (NNS cells)))))) (VP (VBD required) (NP (NP (NN stimulation)) (PP (IN with) (NP (JJ high) (NN antigen) (NN dose))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (TO to) (NP (DT some) (NN extent))) (VP (MD could) (VP (VB be) (VP (VBN compensated) (PRT (IN for)) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN IL-12)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Signaling)) (PP (IN through) (NP (DT the) (NN TCR))) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN antigen)))))) (VP (VBD induced) (NP (NP (JJR stronger) (NN ERK1)) (CC and) (NP (NP (NN ERK2) (NN activation)) (SBAR (WHPP (IN than) (WHNP (WDT that))) (S (VP (VBN induced) (PP (IN by) (NP (JJ low) (NN antigen) (NN dose))) (, ,) (PP (ADVP (RB not) (RB only)) (PP (IN in) (NP (NP (NP (JJ naive) (JJ CD4+) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NP (NNS data)) (ADJP (RB not) (VBN shown))) (-RRB- -RRB-))) (SBAR (IN as) (S (ADVP (RB previously)) (VP (VBN demonstrated) (PRN (-LRB- -LRB-) (NP (NNP Jorritsma) (FW et) (FW al.) (, ,) (CD 2003)) (-RRB- -RRB-))))))) (CC but) (ADVP (RB also)) (PP (IN in) (NP (NP (JJ CD4+) (NN T) (NNS cells)) (VP (VBN restimulated) (PP (IN with) (NP (NP (DT the) (JJ same) (ADJP (ADJP (JJ high)) (CC and) (ADJP (JJ low))) (NN antigen) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5A)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (NP (DT the) (JJ apparent) (NN peak)) (CC and) (NP (NN amount))) (PP (IN of) (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2)) (NP (NN activation))))) (VP (VBD varied) (ADVP (RB slightly)) (PP (IN between) (NP (NNS experiments)))))) (, ,) (NP (DT a) (JJ consistent) (NN finding)) (VP (VBD was) (SBAR (IN that) (S (NP (NP (JJ high) (NN antigen) (NN dose)) (VBN differentiated) (NN Th1) (NNS cells)) (ADVP (RB always)) (VP (VP (VBD showed) (VP (VBN enhanced))) (CC and) (VP (VBD prolonged) (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2) (NN activation))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN IL-12))))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP (PRP they)) (VP (VBD were) (VP (VBN restimulated) (PP (IN with) (NP (NP (ADJP (ADJP (JJ high)) (CC or) (ADJP (JJ low))) (NN antigen) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5B)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2))) (NN activation)) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN IL-10))) (PP (IN in) (NP (NN Th1) (NNS cells))))) (PP (IN by) (S (VP (VBG using) (NP (NP (NP (NN U0126)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5C)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN compound)) (SBAR (WHNP (WDT that)) (S (VP (VBZ blocks) (NP (JJ downstream) (NN ERK) (NN activation)))))))))))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB ensure) (SBAR (IN that) (S (NP (JJ only) (NN T) (NN cell) (NN signaling)) (VP (VBD was) (VP (VBG being) (VP (VBN affected) (PP (IN by) (NP (NN U0126))))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (DT an) (JJ APC-free) (NN system)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN T) (NNS cells)) (VP (VBD were) (VP (VBN differentiated) (PP (IN in) (NP (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (VBG increasing) (NNS doses)) (PP (IN of) (NP (NN anti-CD3)))))) (CC and) (NP (NP (DT a) (JJ constant) (NN amount)) (PP (IN of) (NP (NN IL-12)))))))))))) (. .)))
(S1 (S (S (PP (IN As) (PP (IN in) (NP (DT the) (JJ APC-driven) (NNS cultures)))) (, ,) (NP (NP (JJR stronger) (NN TCR) (NN stimulation)) (PP (ADVP (RB together)) (IN with) (NP (NN IL-12)))) (VP (VBD led) (PP (TO to) (NP (NP (JJR higher) (NNS percentages)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBG producing) (NP (CC both) (NP (NN IL-10)) (CC and) (NP (NN IFN-gamma))) (PP (IN after) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NP (NN culture)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5C)) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (NN U0126))) (PP (TO to) (NP (DT the) (NNS cultures)))) (VP (VBD abrogated) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN IL-10)))) (PP (IN at) (NP (NP (DT all) (NNS doses)) (PP (IN of) (NP (NP (NN anti-CD3)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5C)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN U0126)) (VP (VBZ inhibits) (NP (NP (NP (DT the) (JJ MEK5-catalyzed) (NN activation)) (PP (IN of) (NP (NN ERK5)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (ADJP (ADJP (JJ MEK1-)) (CC and) (ADJP (JJ MEK2-catalyzed))) (NN activation)) (PP (IN of) (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2)))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Bain) (FW et) (FW al.) (, ,) (CD 2007)) (: ;) (NP (NP (NN Mody)) (ADVP (FW et) (FW al.))) (, ,) (NP (CD 2001))) (-RRB- -RRB-))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD used) (NP (NP (NP (DT the) (ADJP (ADJP (RBR more) (JJ specific)) (, ,) (ADJP (RB structurally) (JJ unrelated))) (NN MEK1)) (CC and) (NP (NN MEK2))) (NN inhibitor) (NN PD184352)) (PP (IN at) (NP (NP (NNS concentrations)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (PRP it)) (VP (VBZ inhibits) (NP (NP (NP (NN MEK1)) (CC and) (NP (NN MEK2))) (CONJP (CC but) (RB not)) (NP (NN MEK5))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP Bain) (FW et) (FW al.) (, ,) (CD 2007)) (: ;) (NP (NN Mody))) (ADVP (FW et) (FW al.))) (, ,) (NP (CD 2001))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN PD184352)) (VP (VBD caused) (NP (NP (DT a) (JJ similar) (NN inhibition)) (PP (IN of) (NP (NN IL-10) (NN production))) (PP (IN by) (NP (NN Th1) (NNS cells)))) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN fashion)) (PRN (-LRB- -LRB-) (NP (NP (NN Figure) (CD 5D)) (CC and) (NP (NN Figure) (NN S5A))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (PP (IN Upon) (NP (NP (NN addition)) (PP (IN of) (NP (NNS inhibitors))) (PP (TO to) (NP (NP (JJ other) (NN signaling) (NNS pathways)) (, ,) (PP (VBG including) (NP (NP (NP (DT a) (NN p38) (NN MAPK) (NN inhibitor)) (, ,) (NP (NN SB203580)) (, ,)) (CC or) (NP (NP (DT the) (NN GSK3beta) (NN inhibitor)) (, ,) (NP (NP (NN CT99021)) (PRN (-LRB- -LRB-) (NP (NNP Bain) (FW et) (FW al.) (, ,) (CD 2007)) (-RRB- -RRB-))) (, ,)))))))) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN IL-10) (NN production)))) (VP (VBD was) (VP (VBN observed) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S5B)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (ADVP (RB thus)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NN IL-10) (NN production)) (PP (IN by) (NP (NN Th1) (NNS cells))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ high) (NN antigen) (NN dose)) (CC and) (NP (NN IL-12))))))) (VP (VBZ requires) (NP (NP (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2))) (NN signaling)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NP (NN p38)) (CC or) (NP (DT the) (NN GSK3beta) (NNS pathways))))))))))) (. .)))
